R
Ring Therapeutics
Developed the Anellogy platform. A platform that aims to usher in a new era of programmable medicine by harnessing the natural human commensal virome
About Ring Therapeutics
Ring Therapeutics is a pioneering startup that operates in the biotechnology sector, specifically in the development of programmable genetic medicines. The company's innovative approach involves the use of a commensal virus platform, known as Anellogy™, to engineer viral-based therapies. These therapies are designed to safely and effectively deliver treatments to targeted cells and tissues in the human body.
Read full description
Ring Therapeutics' business model revolves around the development and commercialization of these viral-based therapies. The company's primary clients are patients with significant medical needs who could benefit from these innovative treatments.
The company's unique approach involves harnessing the power of anelloviruses, a type of virus that has evolved over millions of years to be extraordinarily diverse and capable of evading the human immune system. These viruses are not only ubiquitous within the human population, but they also exist in all tissues in the body. By leveraging these unique properties, Ring Therapeutics is developing therapies that can deliver diverse therapeutic modalities to a wide array of tissues.
The company's revenue model is likely based on the sales of these therapies once they have been developed, tested, and approved for use. Given the innovative nature of these therapies, they could potentially command high prices in the market, leading to substantial revenue for the company.
In summary, Ring Therapeutics is a biotech startup that is pushing the boundaries of medicine by developing programmable genetic therapies based on anelloviruses.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Ring Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2023 | $87M | $585M | Partners Investment · Invus · Kyowa Kirin · UPMC Enterprises | ↗ |
| SERIES BOther financing | Jul 2021 | $117M | $468M | UPMC Enterprises · Flagship Pioneering · Partners Investment · Invus | — |
Growth signals
Latest recorded traffic for Ring Therapeutics is 3K monthly website visits, down 18.9% over the last three months. Ring Therapeutics's team declined 23.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Flagship Pioneering
UPMC Enterprises
Partners Investment
Invus
Altitude Life Science Ventures
T. Rowe Price
Series B and later3 investors entered at this stage
Kyowa Kirin
Alexandria Venture Investments
CJ Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ring Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ring Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.